REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Diurnal Group Names Director Sam Williams Interim Chair

Thu, 05th Mar 2020 17:21

(Alliance News) - Diurnal Group PLC on Thursday said Non-Executive Director Sam William will assume the role of interim chair, effective from June 30.

Diurnal's current Non-Executive Chair Peter Allen will step down at the end of June, after a five-year stint.

Williams is the board representative of IP Group PLC, which holds a significant stake in Diurnal. He has over 20 years of experience in the biotechnology industry, both as a top-ranked equity analyst in the city and as an investor and chief executive, the pharmaceutical company said.

He has been on the board of Diurnal since 2015 and held the role of interim chairman prior to the appointment of Allen. He will temporarily replace Allen until a permanent successor is found.

"I would like to thank Peter for his considerable contribution to the company during the past five years. His extensive experience and wise counsel have been invaluable. He leaves Diurnal well-positioned to achieve its vision of becoming a world-leading specialty endocrinology company. We wish him the very best for the future," said Chief Executive Martin Whitaker.

Diurnal shares closed 2.8% lower at 32.45 pence each on Thursday in London.

By Ife Taiwo; ifetaiwo@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
2 Dec 2019 13:19

Diurnal submits application for 'Alkindi Sprinkle' to US FDA

(Sharecast News) - Specialty pharmaceutical company Diurnal Group has submitted a 'New Drug Application' (NDA) to the US Food and Drug Administration (FDA), for the regulatory approval of 'Alkindi Sprinkle', or hydrocortisone granules in capsules for opening, as a replacement therapy of adrenal insufficiency in infants, children and adolescents in the US, it announced on Monday.

Read more
21 Nov 2019 11:36

Diurnal Primary Focus Remains On Progressing Flagship Products

Diurnal Primary Focus Remains On Progressing Flagship Products

Read more
20 Nov 2019 11:36

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Read more
24 Sep 2019 11:21

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Read more
14 Jun 2019 14:26

Diurnal Shareholders Approve Placing, Open Offer Worth GBP6 Million (ALLISS)

(Alliance News) - Pharmaceutical firm Diurnal Group PLC's shareholders on Friday approved its GBP5.9 million fundraise completed earlier in the day.Diurnal, which focuses on patients or

Read more
28 May 2019 13:32

Diurnal Group launches placing and open offer to fund drug development

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced a conditional placing of new ordinary shares in the company and the launch of an open offer on Tuesday, in order to raise funds to progress the development and commercialisation of its products.

Read more
28 May 2019 10:49

Diurnal Raises GBP5 Million Via Placing; Plans GBP1 Million Open Offer (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said Tuesday it has raised around GBP5.4 million via a 20.6 million share placing priced at 26 pence per share and announced an open offer to raise up to

Read more
10 May 2019 09:36

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed a

Read more
24 Apr 2019 15:50

Diurnal gets orphan drug designation for Alkindi in Australia

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that its 'Alkindi' product - hydrocortisone granules in capsules for opening - had been granted orphan drug designation in Australia by the Therapeutic Goods Administration, for the indication 'replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents from birth to 18 years old'.

Read more
24 Apr 2019 10:44

Diurnal Gets Orphan Drug Designation For Alkindi In Australia

LONDON (Alliance News) - Diurnal Group PLC on Wednesday said its adrenal insufficiency drug Alkindi has been granted a second patent and orphan drug designation in Australia.Shares in were

Read more
28 Mar 2019 08:35

Diurnal soars after securing Nordic distribution deal

(Sharecast News) - Diurnal's shares leapt on Thursday despite a widened interim loss as the company landed a marketing and distribution deal for its Alkindi treatment in Scandinavia.

Read more
21 Mar 2019 16:11

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 22 March Sanne GroupFull Year ResultsSmiths GroupHalf Year BootFull Year

Read more
20 Mar 2019 10:33

Diurnal Group upbeat following FDA meeting over 'Alkindi'

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that, following a "positive" meeting with the US Food and Drug Administration (FDA), it intended to submit a new drug application (NDA) for 'Alkindi' (hydrocortisone granules in capsules for opening) in the fourth quarter of 2019 as previously planned, with final acceptance of the filing by the FDA expected in 2020.

Read more
25 Feb 2019 10:39

Diurnal expecting Israel launch of 'Alkindi' next year

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Monday that its marketing and distribution partner, Medison Pharma has successfully submitted a market authorisation application (MAA) for its 'Alkindi' (hydrocortisone granules in capsules for opening) product to the Ministry of Health in Israel.

Read more
10 Jan 2019 12:35

Diurnal Granted US Patent But Unsure Why Share Price Has Tripled

LONDON (Alliance News) - Diurnal Group PLC said on Thursday that, aside from the granting of a patent, it is unsure as to why its share price has tripled.Shares were 188% higher on Thursday

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.